Shenzhen Oculgen Biomedical Technology Co., Ltd.
Shenzhen Oculgen Biomedical Technology Co., Ltd.
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. | Adults With Neovascular Age-related Macular Degeneration | Not yet recruiting | Phase 2 / Phase 3 | 2026-04-13 | NCT07520318 |